Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain

Medicine and Dentistry

• Alzheimer's Disease 83%
• Atorvastatin 66%
• Combination Therapy 50%
• Upregulation 50%
• Oxidative Stress 33%
• Heme 33%
• Oxygenase 33%
• Therapeutic Procedure 33%
• Cognitive Defect 16%
• Enzyme 16%
• Glutathione 16%
• Neuroprotective Agent 16%
• Discrimination Learning 16%
• Memantine 16%
• NMDA Receptor Antagonist 16%
• Liver 16%
• Mechanism of Action 16%
• Neuropathology 16%

Neuroscience

• Parietal Cortex 100%
• Atorvastatin 66%
• Cerebellum 66%
• Oxidative Stress 33%
• Heme 33%
• Oxygenase 33%
• Neurodegenerative Disorder 33%
• Brain 33%
• Cognitive Disorders 16%
• Enzymes 16%
• Neuroprotective Agent 16%
• Glutathione 16%
• N-Methyl-D-Aspartic Acid 16%
• Statin 16%
• Acetylcholinesterase Inhibitor 16%
• Memantine 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Alzheimer Disease 83%
• Atorvastatin 66%
• Heme 33%
• Oxygenase 33%
• Enzyme 16%
• Glutathione 16%
• Neuroprotective Agent 16%
• Cognitive Defect 16%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 16%
• Cholinesterase Inhibitor 16%
• Memantine 16%
• Dog 16%
• Beagle 16%
• N Methyl Dextro Aspartic Acid Receptor Blocking Agent 16%